RayKnowChina Research Map
Shortlist

JinanShandong First Medical University

Central Hospital Affiliated to Shandong First Medical University

山东第一医科大学附属中心医院(济南市中心医院)

Listed for 11 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Central Hospital Affiliated to Shandong First Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  2. Stomach cancer胃癌31 papers led
  3. Lung cancer肺癌59 papers led
  4. Breast cancer乳腺癌21 papers led1 open trial led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Osteosarcoma骨肉瘤6 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  8. Haemophilia A血友病 A1 paper led
  9. Coronary heart disease冠心病6 papers led
  10. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  11. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Pancreatic cancer, Glioma, Hepatoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 112025

6 hospitals in Jinan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07405151

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentRadiotherapy
Departments in papersGastroenterology / hepatologyMedical oncologyPathology / laboratory medicine
Papers it led4
  1. High MRPL12 expression drives esophageal cancer proliferation, invasion and migration.2025Bulletin du cancer
  2. Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.2024Cancer communications (London, England)RCTFree full text
  3. Circ_0006948 Contributes to Cell Growth, Migration, Invasion and Epithelial-Mesenchymal Transition in Esophageal Carcinoma.2022Digestive diseases and sciences
  4. MicroRNA-210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β-catenin signaling pathway and EMT in esophageal squamous cell carcinoma.2021Thoracic cancerFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)RecruitingNCT07405151Study sitePhase 1/Phase 2Start 2026-03
  2. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  3. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  4. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)5
  1. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technologyarticle
  2. 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)2024Annals of Oncologyarticle
  3. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncologyconference-abstract
  4. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 31 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
31
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 4420212022: 5520222023: 7720232024: 9920242025: 552025

7 hospitals in Jinan for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Posted
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  3. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    Phase
    Phase 1
    Started
    2022-02
    Posted
    Registry
    NCT05262491

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyNutrition & recoveryImaging & AI
Departments in papersGastroenterology / hepatologyMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led31
  1. MTF1 attenuates ferroptosis and cuproptosis synergistic potentiation in gastric cancer.2026Cell death and differentiation
  2. DKN-01 Suppresses Gastric Cancer Progression Through Activating cGAS-STING Pathway to Block Macrophage M2 Polarization.2025Applied biochemistry and biotechnology
  3. Helicobacter pylori-induced aberrant methylation of ID4 mediated by DNMT3B drives gastric cancer progression via DEC1-SHH signaling pathway.2025Cell death & diseaseFree full text
  4. GLI2 inhibits cisplatin sensitivity in gastric cancer through DEC1/ZEB1 mediated EMT.2025Cell death & diseaseFree full text
  5. Sanguinarine Inhibits Gastric Cancer Progression by Targeting the NOS2/SOD1 Axis to Promote Ferroptosis.2025The American journal of Chinese medicine
  6. Helicobacter pylori infection induces STAT3/MYBL2/NF-κB axis to promote gastric cancer progression.2025Tissue & cell
  7. A Novel Signature Based on m6A Regulator-Mediated Genes Along Glycolytic Pathway Predicts Prognosis and Immunotherapy Responses of Gastric Cancer Patients.2024Advanced biology
  8. Fabrication of Nickel/Zinc Oxide Nanocomposites from Citrus sinensis Extract Prompts Apoptosis Through Impeding JAK/STAT3 Signaling in Gastric Cancer.2024Applied biochemistry and biotechnology
  9. Effect of Intensive Nursing Management on Quality of Life and Mental Health in Elderly Gastric Cancer Patients Undergoing Chemotherapy: A Retrospective Study.2024British journal of hospital medicine (London, England : 2005)
  10. Positive GLI1/INHBA feedback loop drives tumor progression in gastric cancer.2024Cancer scienceFree full text
  11. Myricetin Induces Ferroptosis and Inhibits Gastric Cancer Progression by Targeting NOX4.2024Journal of agricultural and food chemistry
  12. ROR2 promotes cell cycle progression and cell proliferation through the PI3K/AKT signaling pathway in gastric cancer.2024Molecular carcinogenesis
  13. PKP2 induced by YAP/TEAD4 promotes malignant progression of gastric cancer.2024Molecular carcinogenesis
  14. Virulence gene polymorphisms in Shandong Helicobacter pylori strains and their relevance to gastric cancer.2024PloS oneFree full text
  15. Amino acid deletions at positions 893 and 894 of cytotoxin-associated gene A protein affect Helicobacter pylori gastric epithelial cell interactions.2024World journal of gastroenterologyFree full text
  16. PHKG2 regulates RSL3-induced ferroptosis in Helicobacter pylori related gastric cancer.2023Archives of biochemistry and biophysics
  17. Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.2023BMC medicineFree full text
  18. Targeting Hippo pathway: A novel strategy for Helicobacter pylori-induced gastric cancer treatment.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  19. SUMOylation of TUFT1 is essential for gastric cancer progression through AKT/mTOR signaling pathway activation.2023Cancer scienceFree full text
  20. Clinical and prognostic features of E-cadherin in adenocarcinoma of the esophagogastric junction patients.2023European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  21. Potential Effects of FGFR4 in the Helicobacter pylori-Induced Inflammatory Carcinoma Transformation.2023Gastroenterology
  22. STAT5A modulates gastric cancer progression via upregulation of CD44.2023Genomics
  23. Knockdown circZNF131 Inhibits Cell Progression and Glycolysis in Gastric Cancer Through miR-186-5p/PFKFB2 Axis.2022Biochemical genetics
  24. Relationship between glutathione S-transferase M1 gene polymorphism and gastric cancer.2022Cellular and molecular biology (Noisy-le-Grand, France)
  25. Reciprocal Expression of Differentiated Embryonic Chondrocyte Expressed Genes Result in Functional Antagonism in Gastric Cancer.2022Digestive diseases and sciences
  26. Clinicopathological Significance of STAT3 and p-STAT3 among 91 Patients with Adenocarcinoma of the Esophagogastric Junction.2022Disease markersFree full text
  27. DEC1 promotes progression of Helicobacter pylori-positive gastric cancer by regulating Akt/NF-κB pathway.2022Journal of cellular and molecular medicineFree full text
  28. Effect of LAMA4 on Prognosis and Its Correlation with Immune Infiltration in Gastric Cancer.2021BioMed research internationalFree full text
  29. Long noncoding RNA NR2F1-AS1 plays a carcinogenic role in gastric cancer by recruiting transcriptional factor SPI1 to upregulate ST8SIA1 expression.2021BioengineeredFree full text
  30. Andrographolide Induces Apoptosis in Gastric Cancer Cells through Reactivation of p53 and Inhibition of Mdm-2.2021Doklady. Biochemistry and biophysics
  31. LncPSCA in the 8q24.3 risk locus drives gastric cancer through destabilizing DDX5.2021EMBO reportsFree full text
All its trials on ClinicalTrials.gov, any status13
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorRecruitingNCT05262491Study sitePhase 1Start 2022-02
  3. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  4. Postoperative Adjuvant Therapy for Stage II-III Gastric CancerActive, not recruitingNCT06609759Study siteStart 2024-01
  5. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  6. Minimal Residual Disease-guided Adjuvant Therapy for Gastric CancerActive, not recruitingNCT06157216Study siteN/AStart 2023-10
  7. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Study sitePhase 2Start 2023-02
  8. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  9. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  10. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.TerminatedNCT05188209Study sitePhase 2Start 2021-12
  11. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  12. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  13. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 59 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
59
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
16
led by another institution
Papers led per year
2021: 131320212022: 9920222023: 131320232024: 8820242025: 15152025

9 hospitals in Jinan for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 16

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  2. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  3. Recruiting
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06712316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou

  4. Recruiting
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06712355

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  5. Recruiting
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06758401

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  6. Recruiting
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06890598

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an

  7. Recruiting
    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06892548

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou

  8. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  9. Recruiting
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07111520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou

  10. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07144280

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  11. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  12. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  13. Recruiting
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06010329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  14. Recruiting
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06119581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang

  15. Recruiting
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170788

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou

  16. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicineClinical trials / research unitPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led59
  1. The α5-nAChR/GINS4 axis contributed to nicotine-promoted lung adenocarcinoma progression.2026Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  2. Novel Evolutionarily Conserved Oncogene COA4 is Driven by KRAS Mutant and Promotes Cancer Metastasis Through Dual Mitochondrial Metabolism-Dependent and -Independent Mechanisms.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Clinical evaluation of a novel-developed clone 3E2 for the detection of PD-L1 expression status in lung adenocarcinoma.2025BMC cancerFree full text
  4. Investigation into the Spatial Heterogeneity of Lung Composite Large-Cell Neuroendocrine Carcinoma Spatial Transcriptomic Analysis of Combined Large-Cell Neuroendocrine Carcinoma.2025Cancer biotherapy & radiopharmaceuticals
  5. The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  6. Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer.2025Frontiers in immunologyFree full text
  7. The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.2025Frontiers in immunologyFree full text
  8. Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review.2025Frontiers in immunologyFree full text
  9. ZEB1 Contributes to Drug Resistance Through Canonical Wnt Signaling in Lung Cancer.2025IUBMB life
  10. Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.2025International journal of cancerFree full text
  11. Simultaneous treatment of pulmonary ground-glass opacity nodules with microwave ablation and coaxial puncture biopsy.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  12. Clinical application of microwave ablation combined with coaxial needle biopsy using different sequences for treating lung nodules suggestive of malignancy.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  13. Resolving the spatial and cellular architecture of intra-tumor heterogeneity by multi-region dissection of lung adenocarcinoma.2025Journal of genetics and genomics = Yi chuan xue bao
  14. Correlation of Peripheral Blood CD4/CD8 Ratio with Efficacy and Prognosis in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  15. Prognostic Significance of CD4+ Tumour Infiltrating Lymphocytes in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors Therapy.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  16. The role of glutathione peroxidase 4 in the progression, drug resistance, and targeted therapy of non-small cell lung cancer.2025Oncology researchFree full text
  17. Lung Cancer with Axillary Lymph Node Involvement: A Case Report and Literature Review on a Rare Mode of Metastasis.2024Annals of clinical and laboratory science
  18. Feasibility of an artificial intelligence system for tumor response evaluation.2024BMC medical imagingFree full text
  19. Nicotine promotes M2 macrophage polarization through α5-nAChR/SOX2/CSF-1 axis in lung adenocarcinoma.2024Cancer immunology, immunotherapy : CIIFree full text
  20. Dual-Phase Enhanced CT-Derived Radiomics Nomogram for Progression-Free Survival Prediction in Stage IV Lung Adenocarcinoma.2024Cancer medicineFree full text
  21. Evaluation of an Algorithm for the Segmentation of Lung Nodules in Computerized Tomography Images based on the Automatic Location of a Threshold.2024Current medical imaging
  22. The innovative checkpoint inhibitors of lung adenocarcinoma, cg09897064 methylation and ZBP1 expression reduction, have implications for macrophage polarization and tumor growth in lung cancer.2024Journal of translational medicineFree full text
  23. PLEK2 mediates metastasis and invasion via α5-nAChR activation in nicotine-induced lung adenocarcinoma.2024Molecular carcinogenesis
  24. CALU promotes lung adenocarcinoma progression by enhancing cell proliferation, migration and invasion.2024Respiratory researchFree full text
  25. Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.2023BMC pulmonary medicineFree full text
  26. A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC.2023BMC pulmonary medicineFree full text
  27. Multi-classification model incorporating radiomics and clinic-radiological features for predicting invasiveness and differentiation of pulmonary adenocarcinoma nodules.2023Biomedical engineering onlineFree full text
  28. α5-nAChR/STAT3/CD47 axis contributed to nicotine-related lung adenocarcinoma progression and immune escape.2023Carcinogenesis
  29. Acetylcholine promotes chronic stress-induced lung adenocarcinoma progression via α5-nAChR/FHIT pathway.2023Cellular and molecular life sciences : CMLSFree full text
  30. GRIN2D knockdown suppresses the progression of lung adenocarcinoma by regulating the E2F signalling pathway.2023Cellular signalling
  31. Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.2023Expert review of anticancer therapy
  32. Radiomics nomogram for the prediction of Ki-67 index in advanced non-small cell lung cancer based on dual-phase enhanced computed tomography.2023Journal of cancer research and clinical oncologyFree full text
  33. ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer.2023Journal of cell science
  34. Clinical Study of Artificial Intelligence in Imaging Diagnosis of False Positive Lesions of Pulmonary Nodules.2023Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  35. Heat shock protein B7 (HSPB7) inhibits lung adenocarcinoma progression by inhibiting glycolysis.2023Oncology reportsFree full text
  36. Role of the cGAS-STING pathway in radiotherapy for non-small cell lung cancer.2023Radiation oncology (London, England)Free full text
  37. Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models.2023Translational research : the journal of laboratory and clinical medicine
  38. Comparison of the BOPPPS model and traditional instructional approaches in thoracic surgery education.2022BMC medical educationFree full text
  39. α5-nAChR associated with Ly6E modulates cell migration via TGF-β1/Smad signaling in non-small cell lung cancer.2022Carcinogenesis
  40. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.2022Cell communication and signaling : CCSFree full text
  41. Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants.2022Clinical pharmacology in drug developmentRCT
  42. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.2022Frontiers in immunologyFree full text
  43. The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.2022Human cell
  44. Establishment and Validation of a Novel Nomogram for Predicting Distant Metastasis in Patients with Invasive Lung Adenocarcinoma.2022Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  45. Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC.2022Naunyn-Schmiedeberg's archives of pharmacology
  46. The role of α5-nicotinic acetylcholine receptor/NLRP3 signaling pathway in lung adenocarcinoma cell proliferation and migration.2022Toxicology
  47. Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.2021AgingFree full text
  48. Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.2021BMC cancerFree full text
  49. Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.2021BMC medical imagingFree full text
  50. Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.2021Bioscience reportsFree full text
  51. Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy.2021Cancer communications (London, England)Free full text
  52. ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer.2021Cancer letters
  53. Potential chemotherapeutic effect of betalain against human non-small cell lung cancer through PI3K/Akt/mTOR signaling pathway.2021Environmental toxicology
  54. Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.2021Genes & genomics
  55. Insufficient ablation promotes the metastasis of residual non-small cell lung cancer (NSCLC) cells via upregulating carboxypeptidase A4.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  56. α5-nAChR and survivin: Two potential biological targets in lung adenocarcinoma.2021Journal of cellular physiology
  57. Correlation between Circulating Tumor Cells and Plasma D-dimer and Clinicopathological Characteristics of Patients with Non-small Cell Lung Cancer.2021Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  58. Inhibition Sequence of miR-205 Hinders the Cell Proliferation and Migration of Lung Cancer Cells by Regulating PETN-Mediated PI3K/AKT Signal Pathway.2021Molecular biotechnology
  59. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.2021TheranosticsFree full text
All its trials on ClinicalTrials.gov, any status49
  1. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT07222566Study sitePhase 3Start 2026-01
  2. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Study sitePhase 3Start 2026-04
  3. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Study sitePhase 2Start 2025-06
  4. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.RecruitingNCT06758401Study sitePhase 3Start 2025-07
  5. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Study sitePhase 3Start 2025-12
  6. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingNCT07182682Study sitePhase 3Start 2025-12
  7. Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerRecruitingNCT06712355Study sitePhase 3Start 2025-02
  8. A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerRecruitingNCT06892548Study sitePhase 1/Phase 2Start 2025-05
  9. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingNCT06712316Study sitePhase 2/Phase 3Start 2025-01
  10. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)RecruitingNCT07144280Study sitePhase 3Start 2025-09
  11. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Study sitePhase 3Start 2025-03
  12. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT07111520Study sitePhase 1/Phase 2Start 2025-09
  13. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Study sitePhase 3Start 2023-12
  14. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLCRecruitingNCT06010329Study sitePhase 2Start 2023-12
  15. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Study sitePhase 3Start 2023-12
  16. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Study sitePhase 3Start 2022-03
  17. A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLCActive, not recruitingNCT06883630Study sitePhase 1Start 2025-03
  18. A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)Active, not recruitingNCT06698042Study sitePhase 3Start 2024-11
  19. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active, not recruitingNCT06305754Study sitePhase 3Start 2024-06
  20. A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Active, not recruitingNCT06593522Study sitePhase 2Start 2024-12
  21. A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung CancerActive, not recruitingNCT06984588Study sitePhase 2/Phase 3Start 2024-03
  22. ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsActive, not recruitingNCT05671510Study sitePhase 3Start 2023-06
  23. A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT05844150Study sitePhase 2Start 2023-06
  24. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active, not recruitingNCT06074588Study sitePhase 3Start 2023-11
  25. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Study sitePhase 3Start 2023-02
  26. Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerActive, not recruitingNCT05740566Study sitePhase 3Start 2023-05
  27. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Study sitePhase 3Start 2022-12
  28. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT04921358Study sitePhase 3Start 2021-07
  29. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingNCT05712902Study sitePhase 2Start 2021-07
  30. A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04819100Study sitePhase 3Start 2021-12
  31. A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLCTerminatedNCT04325698Study sitePhase 3Start 2020-06
  32. A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLCStatus unknownNCT04416035Study sitePhase 3Start 2020-08
  33. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  34. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Study sitePhase 1Start 2020-01
  35. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Study sitePhase 3Start 2020-09
  36. A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerCompletedNCT04294810Study sitePhase 3Start 2020-03
  37. A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung CancerCompletedNCT04619797Study sitePhase 2/Phase 3Start 2020-12
  38. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04005716Study sitePhase 3Start 2019-07
  39. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Study sitePhase 2Start 2019-03
  40. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingNCT03974022Study sitePhase 1/Phase 2Start 2019-07
  41. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Study sitePhase 3Start 2018-11
  42. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerCompletedNCT03594747Study sitePhase 3Start 2018-07
  43. A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03735121Study sitePhase 3Start 2018-12
  44. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung CancerCompletedNCT03663205Study sitePhase 3Start 2018-07
  45. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03358875Study sitePhase 3Start 2017-11
  46. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Study sitePhase 1/Phase 2Start 2017-03
  47. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT04237805Study sitePhase 1/Phase 2Start 2016-11
  48. Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Study sitePhase 2Start 2016-09
  49. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung CancerCompletedNCT03117335Study sitePhase 3Start 2011-11

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 21 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
21
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 7720232024: 5520242025: 552025

8 hospitals in Jinan for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07514728

    Age 18 years to 75 years; women only (registered criteria)

    Led by Central Hospital Affiliated to Shandong First Medical UniversityJinan

  2. Recruiting
    A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06738966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Jinan

  3. Recruiting
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06841354

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  4. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  5. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  6. Recruiting
    A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05461768

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Wuhan, Zhengzhou

  7. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicineRadiation oncologyOphthalmology / neuro-ophthalmology
Papers it led21
  1. Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis.2025BMC cancerFree full text
  2. TUFT1 regulates cancer progression by suppressing centrosome amplification and mitotic spindle multipolarity.2025Cell death & diseaseFree full text
  3. Investigating the molecular mechanisms of phytochemicals targeting Ras-related C3 botulinum toxin substrate 1 (Rac1) to inhibit breast cancer metastasis via endoplasmic reticulum stress and Wnt-PCP signaling pathway.2025Journal of molecular modeling
  4. Value of postmastectomy radiotherapy on overall survival in stage II-III node-negative patients following neoadjuvant therapy: A surveillance, epidemiology, and end results-based population study.2025Science progressFree full text
  5. MRI Radiomics-Based Prediction of Occult Sentinel Lymph Node Metastasis and D2-40 Expression in Breast Cancer.2025Technology in cancer research & treatmentFree full text
  6. Prediction of lymphovascular invasion in invasive breast cancer based on clinical-MRI radiomics features.2024BMC medical imagingFree full text
  7. Themis: advancing precision oncology through comprehensive molecular subtyping and optimization.2024Briefings in bioinformaticsFree full text
  8. Study on the differential diagnosis of benign and malignant breast lesions using a deep learning model based on multimodal images.2024Journal of cancer research and therapeutics
  9. Application of rapid rehabilitation surgical concepts in the care of patients with modified radical breast cancer in the perioperative period.2024Minerva surgery
  10. LINC02535 + miR-30a-5p combination enhances proliferation and inhibits apoptosis in metastatic breast Cancer cells.2024Toxicology in vitro : an international journal published in association with BIBRA
  11. Identifying miRNA biomarkers for breast cancer and ovarian cancer: a text mining perspective.2023Breast cancer research and treatment
  12. CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.2023Cancer immunology, immunotherapy : CIIFree full text
  13. The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment.2023Cell transplantationFree full text
  14. Small Bowel Metastases From Malignant Phyllodes Breast Tumor Detected by 18 F-FDG PET/CT.2023Clinical nuclear medicine
  15. SGK1 is involved in doxorubicin-induced chronic cardiotoxicity and dysfunction through activation of the NFκB pathway.2023International immunopharmacology
  16. ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer.2023Journal of cell science
  17. The effects of qigong intervention based on the Internet on quality of life and physical fitness in Chinese postoperative breast cancer patients: a protocol of randomized controlled trial.2023TrialsFree full text
  18. The Significance of Tumor Microenvironment Score for Breast Cancer Patients.2022BioMed research internationalFree full text
  19. Long non-coding RNA PVT1 facilitates cell migration and invasion by regulating miR-148a-3p and ROCK1 in breast cancer.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  20. Clinical Value of Total Intravenous Anesthesia with Sufentanil and Propofol in Radical Mastectomy.2022Disease markersRCTFree full text
  21. Application of fluorescein combined with methylene blue in sentinel lymph node biopsy of breast cancer.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status18
  1. Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric OxygenEnrolling by invitationNCT07514728Lead sponsorN/AStart 2025-11
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Study sitePhase 3Start 2025-03
  3. A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic CancerRecruitingNCT06738966Study sitePhase 1Start 2025-03
  4. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Study sitePhase 3Start 2025-06
  5. A Study of YL202 in Selected Patients With Advanced Solid TumorsRecruitingNCT06107686Study sitePhase 2Start 2023-12
  6. A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerRecruitingNCT05851014Study sitePhase 3Start 2022-01
  7. A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsRecruitingNCT05461768Study sitePhase 1Start 2022-08
  8. Study of ACE-86225106 to Treat Patients With Advanced Solid TumorsActive, not recruitingNCT06380660Study sitePhase 1/Phase 2Start 2024-03
  9. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Study sitePhase 3Start 2023-12
  10. A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingNCT05514054Study sitePhase 3Start 2022-10
  11. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Study sitePhase 3Start 2022-03
  12. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingNCT04961996Study sitePhase 3Start 2021-08
  13. GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT05054751Study sitePhase 3Start 2021-09
  14. A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast CancerStatus unknownNCT04924699Study sitePhase 2/Phase 3Start 2021-06
  15. A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Study sitePhase 3Start 2021-10
  16. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  17. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Study sitePhase 3Start 2016-11
  18. Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast CancerCompletedNCT02482753Study sitePhase 3Start 2015-07

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Jinan for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 332025

18 hospitals in Jinan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led6
  1. Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi-Omics Analysis.2025FASEB journal : official publication of the Federation of American Societies for Experimental BiologyFree full text
  2. The osteosarcoma immune microenvironment in progression: PLEK as a prognostic biomarker and therapeutic target.2025Frontiers in immunologyFree full text
  3. Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies.2025Frontiers in immunologyFree full text
  4. m6A-modified circARHGAP12 promotes the aerobic glycolysis of doxorubicin-resistance osteosarcoma by targeting c-Myc.2024Journal of orthopaedic surgery and researchFree full text
  5. DEPDC1 as a crucial factor in the progression of human osteosarcoma.2023Cancer medicineFree full text
  6. TRIM59 promotes osteosarcoma progression via activation of STAT3.2022Human cell
Earlier papers (2016–2020)5
  1. MiR-196a promoted cell migration, invasion and the epithelial-mesenchymal transition by targeting HOXA5 in osteosarcoma.2020Cancer biomarkers : section A of Disease markers
  2. Silencing of long-non-coding RNA ANCR suppresses the migration and invasion of osteosarcoma cells by activating the p38MAPK signalling pathway.2019BMC cancer
  3. Downregulation of UBE2T can enhance the radiosensitivity of osteosarcoma in vitro and in vivo.2019Epigenomics
  4. Combination of anginex gene therapy and radiation decelerates the growth and pulmonary metastasis of human osteosarcoma xenografts.2018Cancer medicine
  5. β-Aescin shows potent antiproliferative activity in osteosarcoma cells by inducing autophagy, ROS generation and mitochondrial membrane potential loss.2017Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Jinan for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Identification of key genes related to high-risk gastrointestinal stromal tumors using bioinformatics analysis.2018Journal of cancer research and therapeutics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Jinan for haemophilia A132 hospitals in China for haemophilia A

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

  2. Recruiting
    An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT07644832

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Retrospective analysis of clinical data from 171 low-income patients with hemophilia in Shandong Province.2025Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status14
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  2. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Study sitePhase 1/Phase 2Start 2024-05
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  4. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  5. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01
  6. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  7. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia AActive, not recruitingNCT05685238Study sitePhase 3Start 2023-02
  8. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  9. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  10. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  11. A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionCompletedNCT04864743Study sitePhase 1Start 2021-06
  12. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12
  13. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  14. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionStatus unknownNCT03747653Study siteStart 2019-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 6 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 0020242025: 222025

6 hospitals in Jinan for coronary heart disease231 hospitals in China for coronary heart disease

No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led6
  1. Reduced contrast agent volume using a heart-rate dependent and free-breathing scanning protocol in coronary computed tomography angiography (CTA) for patients with chronic obstructive pulmonary disease (COPD).2025BMC cardiovascular disordersRCTFree full text
  2. The Predictive Value of Multiparameter Characteristics of Coronary Computed Tomography Angiography for Coronary Stent Implantation.2025Journal of computer assisted tomography
  3. The effect of gum consumption on blood pressure as a risk factor for coronary heart disease: A meta-analysis of controlled trials.2023International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition
  4. Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.2021Journal of cardiovascular pharmacologyRCTFree full text
  5. Application Effect of Meticulous Nursing on Community Elderly Patients with Coronary Heart Disease under the Background of Medical Treatment Partnerships.2021Journal of healthcare engineeringFree full text
  6. Influence of sex and menopausal status on the relationship between metabolic syndrome and coronary artery calcification: a Chinese community-based cross-sectional study.2021Menopause (New York, N.Y.)
All its trials on ClinicalTrials.gov, any status2
  1. Food Frequency Questionnaire (FFQ) for Coronary Heart Disease (CHD) PatientsCompletedNCT03292055Study siteStart 2017-01
  2. Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World SettingCompletedNCT02565615Study siteStart 2016-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

5 hospitals in Jinan for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led2
  1. Low-dose rituximab for the treatment of anti-NMDAR encephalitis in children: a case series study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Pharmaceutical care of rituximab in the treatment of children with refractory anti-NMDAR encephalitis: A case report.2023MedicineFree full text

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Jinan for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Dual gene deficient models of ApcMin/+ mouse in assessing molecular mechanisms of intestinal carcinogenesis.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山东第一医科大学附属中心医院(济南市中心医院)

Central Hospital Affiliated to Shandong First Medical University

济南

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Jinan Central Hospital; Central Hospital Affiliated to Shandong First Medical University; Jinan Central Hospital Affiliated to Shandong University; Jinan Central Hospital Affiliated to Shandong First Medical University; Jinan Central Hospital. Jinan City; 济南市中心医院

Suggest a correctionDownload the data